Clinical Report: MacroGenics faces ADC safety concerns

MacroGenics is preparing for a Phase III study of antibody-drug conjugate vobramitamab duocarmazine in pancreatic cancer, though the Phase II results last week raised safety concerns that led shares to fall 77% ($11.35) to $3.31 on Friday. 

Five patient deaths were reported in the Phase II TAMARACK study of the B7-H3-directed antibody-drug conjugate from MacroGenics Inc. (NASDAQ:MGNX), serving as a reminder that the ADC efficacy that’s driven an explosion in interest in the modality is often coupled with serious toxicities. ...